BioCentury | Jan 6, 2014
Finance

4Q Stock Wrap-Up: All's well that ends well

Although two segments lost ground in 4Q13, all of biotech's market cap groups finished 2013 in the black. Large caps valued at more than $5 billion led the way in the fourth quarter, tacking on...
BC Week In Review | Oct 7, 2013
Clinical News

BindRen colestilan regulatory update

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that BindRen colestilan from Mitsubishi Tanabe has "no additional benefit" vs. sevelamer or calcium- or aluminum-containing phosphate binders to treat hyperphosphatemia in patients with...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
BC Extra | Oct 2, 2013
Company News

G-BA rebuffs BindRen

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that BindRen colestilan from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508) has "no additional benefit" vs. sevelamer or calcium- or aluminum-containing phosphate binders to treat...
BC Week In Review | Jul 15, 2013
Clinical News

BindRen colestilan regulatory update

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that BindRen colestilan from Mitsubishi is worse than sevelamer to treat hyperphosphatemia in patients with stage 5 chronic kidney disease...
BC Extra | Jul 2, 2013
Company News

IQWiG rebuffs BindRen

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that BindRen colestilan from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508) is worse than sevelamer to treat hyperphosphatemia in patients with...
BC Week In Review | Apr 8, 2013
Company News

Mitsubishi Tanabe Pharma sales and marketing update

Mitsubishi's Mitsubishi Pharma Deutschland GmbH subsidiary launched BindRen colestilan in Germany and Austria to treat hyperphosphatemia in adult patients with stage 5 chronic kidney disease (CKD) receiving hemodialysis or peritoneal dialysis. Mitsubishi said in Germany...
BC Week In Review | Feb 11, 2013
Clinical News

BindRen colestilan regulatory update

The European Commission approved BindRen colestilan from Mitsubishi's Mitsubishi Pharma Europe Ltd. subsidiary to treat hyperphosphatemia in adult patients with stage 5 chronic kidney disease (CKD) receiving hemodialysis or peritoneal dialysis. The product is a...
BioCentury | Feb 12, 2007
Strategy

Outward bound

Outward bound Outward boundWhile neither Mitsubishi nor Tanabe has any marketing presence in the U.S., and Mitsubishi has only a limited marketing presence in Europe, the newco will have retained worldwide rights to a number...
Items per page:
1 - 9 of 9